5. Internationales Liquid Biopsy Symposium 2025 in Freiburg - Blutbasierte Biomarker in der onkologischen Forschung und Praxis – ein Update

Zusammenfassung

Liquid Biopsy, insbesondere Assays zur Bestimmung zirkulierender Tumor-DNA (ctDNA), entwickeln derzeit rasch eine solide Evidenzbasis für den Einsatz in verschiedenen onkologischen Indikationsfeldern. Das 5. Internationale Liquid Biopsy Symposium in Freiburg gab einen Überblick und ein aktuelles Update zur Entwicklung und dem Einsatz etablierter und neuartiger Liquid-Biopsy-Assays in der Tumorforschung und klinischen Versorgung.

• Literatur

• 1 Wiegend K. et al. Aktuelle Entwicklungen zu Liquid Biopsy beim Lungenkarzinom. InFo Hämatologie + Onkologie 2025; 28: 10-14
• 2 Abbosh C. et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends Cancer 2024; 10: 643-654
• 3 Black JRM. et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat Med 2025; 31: 70-76
• 4 Roch B. Harnessing circulating DNA to personalize immunotherapy in early-stage and locally advanced NSCLC. 5th International Liquid Biopsy Symposium 2025
• 5 Moding EJ. et al. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer 2020; 1: 176-183
• 6 Wang Y. et al. Residual ctDNA detection Predicts Benefit from Definitive Chemoradiotharapy and Immune Checkpoint Inhibitors in Locally Advanced NSCLC. ASTRO 2023 Abstract 150
• 7 Cordonnier M. et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles 2020 9. 1710899
• 8 Vautrot V. et al. Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. Cancers (Basel) 2021; 13: 4537
• 9 Gobbo J. Tiny Vesicles, Big Impact: Predicting and Overcoming Resistance to Anti-PD-1/PD-L1. 5th International Liquid Biopsy Symposium 2025
• 10 Nesselbush MC. et al. An ultrasensitive method for detection of cell-free RNA. Nature 2025; 641: 759-768
• 11 Guo X. et al. Clinical effectiveness of urine DNA for minimal residual disease (MRD) monitoring of urothelial carcinoma in urine: A multicenter, prospective, observational study. ASCO-GU 2025 Abstract TPS4617
• 12 Riediger AL. Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancer. medRxiv preprint
• 13 Hendrix A. et al. The nature of blood(y) extracellular vesicles. Nat Rev Mol Cell Biol 2021; 22: 243